News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TARGET PharmaSolutions Partners With Bristol-Myers Squibb (BMY), Offering A New Platform To Collect Real World Data



11/11/2016 10:28:21 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

CHAPEL HILL, N.C., Nov. 10, 2016 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce two new collaborations with Bristol-Myers Squibb (BMY) to advance the understanding of treatment patterns in nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The TARGET model provides pharmaceutical and biotechnology partners access to a robust disease state registry that is also linked to a biorepository and patient reported outcomes, providing unique data and insights compared to typical patient registries.

"The unique collaboration with Bristol-Myers Squibb across both NASH and HCC will ensure that we are able to further provide the hepatology and oncology community with important insights across multiple conditions affecting the liver, especially as these conditions continue to develop into growing public health issues," said Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions. The impact of the TARGET platform will help pharmaceutical partners better understand multiple elements of disease etiology, treatment modalities, and outcomes.

TARGET-NASH's first patient enrollment occurred August 1, 2016. The company plans on enrolling up to 15,000 patients, at up to 100 sites worldwide. TARGET-HCC's first patient enrollment is set for Q4 2016. The company plans on enrolling up to 5,000 patients worldwide, at up to 75 sites in the US and Europe.

TARGET PharmaSolutions was formed in February 2015 and currently has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 10,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.

About TARGET PharmaSolutions

TARGET PharmaSolutions is a privately held clinical data company that provides pharmaceutical and biotechnology partners a more efficient way to generate data that can be used to better understand the natural history of diseases, including treatment outcomes in the real world setting. TARGET PharmaSolutions is based in Chapel Hill, N.C. For more information, visit www.targetpharmasolutions.com 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/target-pharmasolutions-partners-with-bristol-myers-squibb-offering-a-new-platform-to-collect-real-world-data-300360663.html

SOURCE TARGET PharmaSolutions, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES